Agios Pharmaceuticals (LTS:0HB0) Cyclically Adjusted PB Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0HB0 Agios Pharmaceuticals Inc LTS:0HB0
45 GF Score
Price $33.09
GF Value $129.42
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Agios Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Agios Pharmaceuticals  (LTS:0HB0) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Agios Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms


Agios Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Agios Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agios Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Agios Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.44 2.18 1.58 2.11 1.61

Agios Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.94 2.25 1.52 1.90 2.02

LTS:0HB0 vs GENB, ZYME, ZBIO: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Agios Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agios Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


LTS:0HB0
45GF Score
Agios Pharmaceuticals Inc LTS:0HB0
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Agios Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Agios Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Agios Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=17.214/333.9520*333.9520
=17.214

Current CPI (Jun. 2026) = 333.9520.

Agios Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201609 9.555 241.428 13.217
201612 8.493 241.432 11.748
201703 7.252 243.801 9.934
201706 10.528 244.955 14.353
201709 9.252 246.819 12.518
201712 7.691 246.524 10.419
201803 15.043 249.554 20.130
201806 14.209 251.989 18.831
201809 13.069 252.439 17.289
201812 11.810 251.233 15.698
201903 10.574 254.202 13.891
201906 9.067 256.143 11.821
201909 7.614 256.759 9.903
201912 9.364 256.974 12.169
202003 9.090 258.115 11.761
202006 8.087 257.797 10.476
202009 6.943 260.280 8.908
202012 5.765 260.474 7.391
202103 32.897 264.877 41.476
202106 28.740 271.696 35.325
202109 25.491 274.310 31.033
202112 23.778 278.802 28.482
202203 22.043 287.504 25.604
202206 20.506 296.311 23.111
202209 19.131 296.808 21.525
202212 20.000 296.797 22.504
202303 18.662 301.836 20.648
202306 17.300 305.109 18.935
202309 15.869 307.789 17.218
202312 14.497 306.746 15.783
202403 13.108 312.332 14.015
202406 11.613 314.175 12.344
202409 28.527 315.301 30.214
202412 26.960 315.605 28.527
202503 25.334 319.799 26.455
202506 23.597 322.561 24.430
202509 22.037 324.800 22.658
202512 20.413 324.054 21.037
202603 18.690 330.213 18.902
202606 17.214 333.952 17.214

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Agios Pharmaceuticals (LTS:0HB0) Overvalued in 2026?

Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued. The current stock price of $33.09 is trading 74.4% below its estimated GF Value™ of $129.42. GuruFocus considers Agios Pharmaceuticals to be Possible Value Trap.

Key valuation signals for LTS:0HB0:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $129.42 vs. price of $33.09 (74.4% below fair value)
  • GF Score™: 45/100 with 3 warning signs

No single metric tells the full story. See the LTS:0HB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Agios Pharmaceuticals Business Description

Other Exchanges AGIO:USA8AP:Germany
Address 88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
45GF Score

Get the complete analysis for LTS:0HB0

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$33.09
Price
$129.42
GF Value